Palisade Bio Secures FDA Clearance for Ulcerative Colitis Drug Trial

By EC Assets · Published 29 June 2026

Palisade Bio shares rose following the U.S. Food and Drug Administration's (FDA) clearance of its Investigational New Drug (IND) application for PALI-2108. The FDA clearance enables the company to proceed with human trials for the drug candidate. PALI-2108 is intended for the treatment of ulcerative colitis (UC). The clearance facilitates the initiation of the global Phase 2 ASCENTRA-UC study. This clinical trial will target patients with moderately to severely active ulcerative colitis. Palisade Bio plans to begin this global Phase 2 study in the second half of 2027. Palisade Bio Inc. made the announcement on June 29, 2026. Prior to this clearance, PALI-2108 demonstrated supportive data from Phase 1a and Phase 1b studies. The ASCENTRA-UC study is expected to enroll both moderately and severely active ulcerative colitis patients. The company's stock trades under the NASDAQ ticker PALI. This article is intended for informational purposes only. It does not constitute investment advice.